Financial Performance - The company's reported net sales reached $5061 billion, demonstrating a 228% increase year-over-year[21] - Operational net sales grew by 216% year-over-year[14] - Organic net sales increased by 174% compared to the previous year[14] - Reported earnings per share (EPS) stood at $053, compared to $022 in Q2 2024[18] - Adjusted EPS was $075, up from $062 in Q2 2024[18] - The company's free cash flow reached $1129 million in Q2 2025, compared to $660 million in Q2 2024[35] Segment Performance - MedSurg segment reported net sales of $1716 billion, a 157% increase year-over-year[22] - Cardiovascular segment reported net sales of $3345 billion, a 268% increase year-over-year[25] - Cardiology segment net sales increased by 293% to $2647 billion[27] - Electrophysiology (EP) net sales surged by 961% to $840 million[27] Guidance - The company projects Q3 2025 reported net sales growth of 17%-19% and organic net sales growth of 12%-14%[18] - Q3 2025 reported EPS is expected to be $044-$046, with adjusted EPS of $070-$072[18] - For the full year 2025, the company anticipates reported net sales growth of 18%-19% and organic net sales growth of 14%-15%[18] - Full year 2025 reported EPS is projected to be $189-$193, with adjusted EPS of $295-$299[18]

Core Viewpoint - Boston Scientific Corporation has announced a definitive agreement to acquire SoniVie Ltd., aiming to enhance its offerings in interventional cardiology therapies with the TIVUS™ Intravascular Ultrasound System for treating hypertension [1][4]. Company Summary - Boston Scientific is acquiring a 90% stake in SoniVie for an upfront payment of approximately $360 million, with potential additional payments of up to $180 million based on regulatory milestones [4][5]. - The acquisition is expected to be completed in the first half of 2025, subject to customary closing conditions [4]. - The transaction is anticipated to be slightly dilutive to adjusted earnings per share (EPS) in 2025, with the company planning to offset this through internal cost efficiencies [4]. Industry Summary - Hypertension is a major risk factor for cardiovascular disease, and current treatments often fall short in effectively controlling high blood pressure [2]. - The TIVUS system is designed to perform renal denervation (RDN), which may serve as an alternative or adjunctive therapy to existing anti-hypertensive medications [2][3]. - The TIVUS system utilizes ultrasound energy, which can penetrate tissue more deeply than radiofrequency energy, potentially leading to faster procedures and effective nerve ablation [2][3].